Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains

Transfusion

Volumn 55, Issue 9, 2015, Pages 2104-2112

  Schmidt, Michael ^a,d   Hourfar, Michael K ^a   Sireis, Walid ^a   Pfeiffer, Ulrich ^a   Göttig, Stephan ^b   Kempf, Volkhard A J ^b   McDonald, Carl P ^c   Seifried, Erhard ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d University of Ulm   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ARTICLE; BACILLUS CEREUS; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL STRAIN; BLOOD COMPONENT; CLINICAL EFFECTIVENESS; INOCULATION; KLEBSIELLA PNEUMONIAE; NONHUMAN; PATHOGEN INACTIVATION; PATHOGEN REDUCTION SYSTEM; SERRATIA MARCESCENS; SHELF LIFE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PYOGENES; BLOOD SAFETY; DISINFECTION; DONOR SELECTION; EVALUATION STUDY; HUMAN; MICROBIAL VIABILITY; MICROBIOLOGY; PLASMA; PROCEDURES; THROMBOCYTE;

BACILLUS CEREUS; BLOOD PLATELETS; BLOOD SAFETY; DISINFECTION; DONOR SELECTION; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL VIABILITY; PLASMA;

EID: 84941804676     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13171     Document Type: Article

References (51)

1. Kal EF,. Conflicted caregivers. Am J Psychiatry 2000; 157: 305.
2. Dodd RY,. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159: 135-42.
3. Offergeld R., [Blood-surely but safely!]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 905-6.
4. Sireis W, Hourfar MK, Seifried E, et al., How to improve blood safety with respect to bacterial contaminations? Vox Sang 2012; 103: 87-8.
5. Hourfar MK, Jork C, Schottstedt V, et al,. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008; 48: 1558-66.
6. Schrezenmeier H, Walther-Wenke G, Müller TH, et al., Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644-52.
7. de Korte D, Curvers J, de Kort WL, et al., Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006; 46: 476-85.
8. de Korte D, Marcelis JH, Verhoeven AJ, et al., Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang 2002; 83: 13-6.
9. McDonald CP, Roy A, Mahajan P, et al., Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang 2004; 86: 178-82.
10. Riedel S, Siwek G, Beekmann SE, et al., Comparison of the BACTEC 9240 and BacT/Alert blood culture systems for detection of bacterial contamination in platelet concentrates. J Clin Microbiol 2006; 44: 2262-4.
11. Espasa M, Salvado M, Vicente E, et al., Evaluation of the VersaTREK system compared to the Bactec MGIT 960 system for first-line drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2012; 50: 488-91.
12. Martinez RM, Bauerle ER, Fang FC, et al., Evaluation of three rapid diagnostic methods for direct identification of microorganisms in positive blood cultures. J Clin Microbiol 2014; 52: 2521-9.
13. Dumont LJ, Kleinman S, Murphy JR, et al., Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010; 50: 589-99.
14. Fang CT, Chambers LA, Kennedy J, et al., Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion 2005; 45: 1845-52.
15. Ramírez-Arcos S, Kou Y, Mastronardi C, et al., Bacterial screening of outdated buffy coat platelet pools using a culture system and a rapid immunoassay. Transfusion 2011; 51: 2566-72.
16. te Boekhorst PA, Beckers EA, Vos MC, et al., Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005; 45: 514-9.
17. Montag T,. Strategies of bacteria screening in cellular blood components. Clin Chem Lab Med 2008; 46: 926-32.
18. Murphy WG, Coakley P,. Testing platelet components for bacterial contamination. Transfus Apher Sci 2011; 45: 69-74.
19. Owusu-Ofori S, Temple J, Sarkodie F, et al., Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005; 45: 133-40.
20. Polewczyk A, Janion M, Podlaski R, et al., Clinical manifestations of lead-dependent infective endocarditis: analysis of 414 cases. Eur J Clin Microbiol Infect Dis 2014; 33: 1601-8.
21. Irsch J, Lin L,. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011; 38: 19-31.
22. Osselaer JC, Messe N, Hervig T, et al., A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-71.
23. Jocic M, Trkuljic M, Jovicic D, et al., Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model. Vojnosanit Pregl 2011; 68: 1041-6.
24. Schubert P, Culibrk B, Coupland D, et al., Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397-408.
25. Vanlandingham DL, Keil SD, Horne KM, et al., Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-90.
26. Lobo SL, Mehta N, Forgione AG, et al., Use of Theraflex-TMJ topical cream for the treatment of temporomandibular joint and muscle pain. Cranio 2004; 22: 137-44.
27. Politis C, Kavallierou L, Hantziara S, et al., Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007; 92: 319-26.
28. Seltsam A, Müller TH,. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38: 43-54.
29. Dodd R, Kurt Roth W, Ashford P, et al., Transfusion medicine and safety. Biologicals 2009; 37: 62-70.
30. Postma MJ, van Hulst M, De Wolf JT, et al., Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005; 15: 379-87.
31. Rock G,. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-78.
32. Ruane PH, Edrich R, Gampp D, et al., Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
33. Stramer SL,. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014; 9: 30-6.
34. Mejia YX, Mao H, Forde NR, et al., Thermal probing of E. coli RNA polymerase off-pathway mechanisms. J Mol Biol 2008; 382: 628-37.
35. Tassou CC, Panagou EZ, Samaras FJ, et al., Temperature-assisted high hydrostatic pressure inactivation of Staphylococcus aureus in a ham model system: evaluation in selective and nonselective medium. J Appl Microbiol 2008; 104: 1764-73.
36. Wong TL, Whyte RJ, Graham CG, et al., Growth of enterotoxigenic Staphylococcus aureus in povi masima, a traditional Pacific island food. J Appl Microbiol 2004; 97: 1185-91.
37. Benjamin RJ, Dy B, Perez J, et al., Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results. Vox Sang 2014; 106: 23-30.
38. Eder AF, Kennedy JM, Dy BA, et al., Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007; 47: 1134-42.
39. Niu MT, Knippen M, Simmons L, et al., Transfusion-transmitted Klebsiella pneumoniae fatalities, 1995 to 2004. Transfus Med Rev 2006; 20: 149-57.
40. Sazama K,. Bacteria in blood for transfusion. A review. Arch Pathol Lab Med 1994; 118: 350-65.
41. Jacobs MR, Good CE, Lazarus HM, et al., Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 2008; 46: 1214-20.
42. Seltsam A, Müller TH,. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162: 442-54.
43. Störmer M, Arroyo A, Brachert J, et al., Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup on bacteria. Vox Sang 2012; 102: 22-31.
44. Goodrich RP, Edrich RA, Li J, et al., The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
45. Seghatchian J, Tolksdorf F,. Characteristics of the theraflex UV-platelets pathogen inactivation system-an update. Transfus Apher Sci 2012; 46: 221-9.
46. Kwon SY, Kim IS, Bae JE, et al., Pathogen inactivation efficacy of Mirasol PRT System and INTERCEPT Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014; 107: 254-60.
47. Funk MB, Lohmann A, Guenay S, et al., Transfusion-transmitted bacterial infections-haemovigilance data of German blood establishments (1997-2010). Transfus Med Hemother 2011; 38: 266-71.
48. Dreier J, Vollmer T, Kleesiek K,. Novel flow cytometry-based screening for bacterial contamination of donor platelet preparations compared with other rapid screening methods. Clin Chem 2009; 55: 1492-502.
49. Sireis W, Rüster B, Daiss C, et al., Extension of platelet shelf life from 4 to 5 days by implementation of a new screening strategy in Germany. Vox Sang 2011; 101: 191-9.
50. Vollmer T, Dreier J, Schottstedt V, et al., Detection of bacterial contamination in platelet concentrates by a sensitive flow cytometric assay (BactiFlow): a multicentre validation study. Transfus Med 2012; 22: 262-71.
51. Vollmer T, Knabbe C, Dreier J,. Novel flow cytometric screening method for bacterial contamination of red blood cells: a proof-of-principle evaluation. Transfusion 2014; 54: 900-9.